{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:19Z","timestamp":1788498919354,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The standard first-line R-CHOP regimen achieves cure in only approximately 50% of patients. Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting the B-cell receptor component CD79b; however, evidence regarding its real-world efficacy remains relatively limited. This retrospective study aims to evaluate the clinical efficacy of Pola in combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 140 patients with complete clinical records treated at the Affiliated Hospital of Qingdao University between September 2022 and September 2025. Among them, 114 patients received combination regimens containing Pola, while 26 patients received regimens without Pola. Given the limited follow-up duration, this study primarily assessed interim efficacy, with preliminary survival data also reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 140 eligible patients, 4 deaths and 20 disease progressions occurred. The age range was 23\u201391, with a median age of 67; 45.0% were female. An ECOG performance status \u22652 was observed in 16.4% of patients, and 20.7% presented with B symptoms. Elevated LDH levels were found in 57.9% of patients. Ann Arbor stage III or IV disease was present in 65.0% of patients, and an IPI score &amp;gt;2 was recorded in 50.7%. Double-expressor lymphoma was diagnosed in 40.0% of cases. Bone marrow involvement was detected in 20.0% of patients, while 83.6% had lymph node extracapsular extension. Immunohistochemistry staining showed 36 patients (25.7%) with GCB subtype and 99 patients (70.7%) with non-GCB subtype. Median follow-up was 11 months (95% CI: 10.85\u201313.15). The objective response rate (ORR) was 94.4% in the Pola group and 70.0% in the non-Pola group (OR\u00a0=\u00a07.1, 95% CI: 2.0\u201327.2, P&amp;lt;0.001). Complete remission (CR) rates were 53.7% and 20.0%, respectively (OR\u00a0=\u00a04.6, 95% CI: 1.7\u201314.9, P\u00a0=\u00a00.002). The Pola group showed a statistically significant advantage in progression-free survival (PFS). Six-month PFS rates were 90.4% (95% CI: 84.8%\u201396.3%) for the Pola group and 76.9% (95% CI: 62.3%\u201394.9%) for the non-Pola group, while 12-month PFS rates were 87.2% (95% CI: 80.5%\u201394.6%) and 67.9% (95% CI: 51.7%\u201389.2%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combination regimens containing Polatuzumab vedotin demonstrated a marked interim efficacy advantage, which may translate into potential long-term survival benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1847437","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:40Z","timestamp":1788495880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interim efficacy and preliminary survival outcomes of polatuzumab vedotin in combination for diffuse large B-cell lymphoma: a retrospective real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Songshen","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100750","article-title":"How I treat diffuse large B-cell lymphoma","volume":"8","author":"Melchardt","year":"2023","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100441","article-title":"Fifth edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell neoplasms","volume":"37","author":"Medeiros","year":"2024","journal-title":"Mod Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223857","article-title":"First-line combination of R-CHOP with the PDE4 inhibitor roflumilast for high-risk DLBCL","volume":"16","author":"Duque","year":"2024","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.011","article-title":"Refractory DLBCL: challenges and treatment","volume":"22","author":"Goldfinger","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05880-z","article-title":"Advances in biology, diagnosis and treatment of DLBCL","volume":"103","author":"Shi","year":"2024","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70153","article-title":"Management of primary refractory diffuse large B-cell lymphoma in patients unsuitable for CAR T-cell therapy","volume":"116","author":"Caserta","year":"2026","journal-title":"Eur J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010010","article-title":"B-cell receptor signaling and beyond: The role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in normal and Malignant B cells","volume":"25","author":"Tkachenko","year":"2023","journal-title":"IJMS"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00572-7","article-title":"Polatuzumab vedotin: A new target for B cell Malignancies","volume":"15","author":"Choi","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04711-9","article-title":"Polatuzumab vedotin\u2013based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: A real-world experience","volume":"101","author":"Wang","year":"2022","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71531","article-title":"Real\u2010world outcomes of polatuzumab vedotin plus R\u2010CHP versus R\u2010CHOP\u2010based regimens in Japanese patients with untreated diffuse large B\u2010cell lymphoma","volume":"15","author":"Hotta","year":"2026","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70280","article-title":"Efficacy and relapse profiles of Pola\u2010R\u2010CHP versus R\u2010CHOP in previously untreated diffuse large B\u2010cell lymphoma: A multicentre real\u2010world study","volume":"208","author":"Terao","year":"2026","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70017","article-title":"Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B\u2010cell lymphoma: A real\u2010world, multi\u2010center, retrospective cohort study","volume":"43","author":"Zhao","year":"2025","journal-title":"Hematological Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL: An Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00789","article-title":"Mid-treatment response to 177-lutetium dotatate predicts overall outcome in patients with advanced neuroendocrine tumors","volume":"20","author":"Halperin","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25712","article-title":"Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia","volume":"95","author":"Castillo","year":"2020","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106700","article-title":"Factors affecting survival in elderly patients with diffuse large B-cell lymphoma","volume":"110","author":"Ulu","year":"2021","journal-title":"Leuk Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16377","article-title":"The prognostic significance of MYC\/BCL2 double expression in DLBCL in the genetic classification era","volume":"116","author":"Wu","year":"2025","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070300","article-title":"Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index","volume":"110","author":"Chung","year":"2007","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011408","article-title":"Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP","volume":"8","author":"Bantilan","year":"2024","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/897178","article-title":"Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients","volume":"2012","author":"Huang","year":"2012","journal-title":"Sci World J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2392","article-title":"Cell-of-origin subtype predicts response to polatuzumab vedotin in large B-cell lymphoma","volume":"32","author":"Cliff","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_446","article-title":"Impact of response to holding\/bridging therapy in second\u2010line DLBCL patients treated with axicabtagene ciloleucel: A LYSA study from the French DESCAR\u2010T registry","volume":"43","author":"Capes","year":"2025","journal-title":"Hematological Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/1471-0528.15505","article-title":"The implications of non\u2010compliance: Randomised controlled trials: The intention\u2010to\u2010treat principle","volume":"126","author":"Platt","year":"2019","journal-title":"BJOG"},{"key":"B31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jclinepi.2020.04.023","article-title":"Rethinking the intention-to-treat principle: One size does not fit all","volume":"125","author":"Oude Rengerink","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:41Z","timestamp":1788495881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1847437"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1847437","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1847437"}}